🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049

Found 15 matching trials

An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa

PHASE3

The purpose of this study is to conduct long-term surveillance for efficacy...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-18

Trial ID

NCT02207816

Treatments Being Tested

Blood sampling Malaria Vaccine 257049 (MALARIA-055 PRI)Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)Cell-culture rabies vaccine (MALARIA-055 PRI)TritanrixHepB/Hib (MALARIA-055 PRI)Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

PHASE2

MALARIA-092 (NCT03162614) study was designed to evaluate the efficacy, immu...

Status

Completed

Location

GSK Investigational Site

Start Date

2019-02-05

Trial ID

NCT03824236

Treatments Being Tested

RTS,S/AS01E (SB257049)

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

PHASE2

This study is designed to evaluate efficacy, immunogenicity and safety of v...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-05-24

Trial ID

NCT03162614

Treatments Being Tested

RTS,S/AS01E RTS,S/AS01B Sporozoite-infected mosquitoes challenge.

Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

PHASE3

The purpose of this observer-blind study is to gather key efficacy, safety,...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-03-27

Trial ID

NCT00866619

Treatments Being Tested

Malaria Vaccine 257049 Meningococcal C Conjugate Vaccine Cell-culture rabies vaccine TritanrixHepB/Hib Polio Sabin Oral Polio Vaccine (GSK)

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

PHASE2

The study intends to establish proof of concept for a fractional dose sched...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-09-28

Trial ID

NCT03276962

Treatments Being Tested

RTS,S/AS01E (Full dose)RTS,S/AS01E (1/5th dose)Rabies vaccine

Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen

PHASE2

This study is being done to assess the possibility of the potential integra...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-04-30

Trial ID

NCT00436007

Treatments Being Tested

GSK 257049 Tritanrix™ HepB/Hib Rouvax™Stamaril™Polio Sabin™

Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children

PHASE2

GSK Biologicals is developing a number of candidate malaria vaccines for th...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-04-07

Trial ID

NCT00307021

Treatments Being Tested

GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049

Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yearly Booster of the RTS,S/AS01E Vaccine, as Part of Their Participation in the Malaria-094 (204889/NCT03276962) Study.

N/A

The aim of this study was to evaluate the effectiveness of the RTS,S/AS01E ...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-11-19

Trial ID

NCT03281291

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

PHASE3

The purpose of this study is to assess the immunogenicity, safety, and reac...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-05-10

Trial ID

NCT02699099

Treatments Being Tested

Vitamin A Candidate Plasmodium falciparum malaria vaccine MR-Vac Stamaril

Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.

PHASE2

This phase IIb trial is being done to find out if the RTS,S/AS01 vaccine he...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-01-03

Trial ID

NCT00380393

Treatments Being Tested

GSK malaria vaccine 257049 Vaccine Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine

Previous Next